Vannetoclax: A New BCL2 Inhibitor

Vannetoclax is currently being wrapped up over five weeks. This drug seems to be very, very safe and has maybe the best toxicity profile of all BTK inhibitors. AHP-53 disrupted patients seem to maybe starting to separate themselves out. But in general, all comers, no matter what risk or what genetic features you might have, are doing phenomenally well,. And we're getting at least another year median extended in terms of outcome and efficacy.